Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13230295 | 0.77 | PIK3CG (0.36) | PIK3CG | |
| Hydrochloric Acid SCHEMBL2392011 | 0.76 | PIK3CG (0.35) | PIK3CG | |
| SCHEMBL12310289 | 0.74 | PIK3CG (0.31) | PIK3CG | |
| SCHEMBL14942714 | 0.74 | CHRM2 (0.39) | CNR2LMNAGAASMN1; SMN2 | |
| SCHEMBL22347673 | 0.73 | NR1H4 (0.41) | — | |
| SCHEMBL29784248 | 0.72 | HTT (0.41) | PIK3CGMGLLSMN1; SMN2 | |
| SCHEMBL22348525 | 0.71 | NR1H4 (0.42) | — | |
| SCHEMBL22348690 | 0.70 | NR1H4 (0.35) | — | |
| SCHEMBL12259390 | 0.70 | FABP4 (0.31) | — | |
| SCHEMBL12835653 | 0.69 | CNR2 (0.32) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029377-B2 | Platelet-activating factor receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-05-12 | — | — | US | disclosed |
| US-8440672-B2 | Diphenyl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-05-03 | — | — | US | disclosed |
| US-20100168076-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | PTAFR, PAFAH1B2, PAFAH1B3 | PIK3CG 1193/4885CNR2 91/4885MGLL 451/4885 |
| US-20100168076-A1 | DIPHENYL SUBSTITUTED ALKANES | ALOX5, ALOX15, ALOX15B | PIK3CG 3531/4885CNR2 826/4885MGLL 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.